Clinical Infectious Diseases · 2020 · 121 citations · 28 references
Veterinary MedicineImmunologyInfectious DiseasesClinical ImmunologyImmunology Of Infectious DiseasesMolecular VirologyAntibody CharacterizationRespiratory Infectious DiseasesSerological DiagnosticsViral InfectionsAntibodiesSars-cov-2 InfectionSevere Acute Respiratory SyndromeSymptom Onset Timing
BACKGROUND: Reports suggest that some persons previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lack detectable immunoglobulin G (IgG) antibodies. We aimed to determine the proportion IgG seronegative and predictors for seronegativity among persons previously infected with SARS-CoV-2. METHODS: We analyzed serologic data collected from healthcare workers and first responders in New York City and the Detroit metropolitan area with a history of a positive SARS-CoV-2 reverse-transcription polymerase chain reaction (RT-PCR) test result and who were tested for IgG antibodies to SARS-CoV-2 spike protein at least 2 weeks after symptom onset. RESULTS: Of 2547 persons with previously confirmed SARS-CoV-2 infection, 160 (6.3%) were seronegative. Of 2112 previously symptomatic persons, the proportion seronegative slightly increased from 14 to 90 days post symptom onset (P = .06). The proportion seronegative ranged from 0% among 79 persons previously hospitalized to 11.0% among 308 persons with asymptomatic infections. In a multivariable model, persons who took immunosuppressive medications were more likely to be seronegative (31.9%; 95% confidence interval [CI], 10.7%-64.7%), while participants of non-Hispanic Black race/ethnicity (vs non-Hispanic White; 2.7%; 95% CI, 1.5%-4.8%), with severe obesity (vs under/normal weight; 3.9%; 95% CI, 1.7%-8.6%), or with more symptoms were less likely to be seronegative. CONCLUSIONS: In our population with previous RT-PCR-confirmed infection, approximately 1 in 16 persons lacked IgG antibodies. Absence of antibodies varied independently by illness severity, race/ethnicity, obesity, and immunosuppressive drug therapy. The proportion seronegative remained relatively stable among persons tested up to 90 days post symptom onset.
28
Antibody responses to SARS-CoV-2 in patients with COVID-19
Quanxin Long, Bai-Zhong Liu, Haijun Deng et al. · Nature Medicine · 2020 · 3.1K citations · Full text
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Quanxin Long, Xiao-Jun Tang, Q L Shi et al. · Nature Medicine · 2020 · 3.1K citations · Full text
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Davide F. Robbiani, Christian Gaebler, Frauke Muecksch et al. · Nature · 2020 · 2.1K citations · Full text